Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind trial of crenezumab in prodromal to mild Alzheimer's disease
jRCT2080223539Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Crenezumab with Placebo (2 arms). Started May 2017; status: completed.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223539.